{"id":"daxi-for-injection-250-u","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Muscle weakness"},{"rate":null,"effect":"Eyelid ptosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"DAXI (DaxibotulinumtoxinA) is a novel botulinum toxin serotype A product engineered with a proprietary peptide excipient (RTP004) designed to enhance potency and duration of action. It works by cleaving SNARE proteins at the neuromuscular junction, preventing acetylcholine vesicle release and thereby reducing unwanted muscle contractions. The formulation aims to provide longer-lasting effects compared to existing botulinum toxin products.","oneSentence":"DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:25.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glabellar lines (frown lines) in adults"},{"name":"Cervical dystonia"}]},"trialDetails":[{"nctId":"NCT03821402","phase":"PHASE2","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2018-12-12","conditions":"Upper Limb Spasticity","enrollment":83}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DAXI for injection 250 U","genericName":"DAXI for injection 250 U","companyName":"Revance Therapeutics, Inc.","companyId":"revance-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Glabellar lines (frown lines) in adults, Cervical dystonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}